The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10237 malaria professionals are enjoying the free benefits of MalariaWorld today

chloroquine

Splenic architecture disruption and parasite-induced splenocyte activation and anergy in Plasmodium falciparum-infected Saimiri sciureus monkeys

March 31, 2015 - 17:25 -- Open Access
Author(s): 
Francisco A Alves, Marcelo Pelajo-Machado, Leonardo Carvalho, et al.
Reference: 
Malaria Journal 2015, 14:128 (25 March 2015)

Inability to eliminate haemozoin is likely involved in the persistent lymphocyte activation and in the anergic responses of Saimiri splenocytes to P. falciparum pRBC, with important negative impact in immune responses and implications for the design of malaria vaccine.

Medical Treatment: 

Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo

March 24, 2015 - 08:59 -- Open Access
Author(s): 
Adeshina I. Adekunle, Mykola Pinkevych, Rose McGready, Christine Luxemburger, Lisa J. White, François Nosten, Deborah Cromer, Miles P. Davenport
Reference: 
PLoS Negl Trop Dis 9(3): e0003595

The dynamics of Plasmodium vivax infection is characterized by reactivation of hypnozoites at varying time intervals.

Medical Treatment: 

NOT Open Access | N10,N11-di-alkylamine indolo[3,2-b]quinolines as hemozoin inhibitors: Design, synthesis and antiplasmodial activity

March 16, 2015 - 08:49 -- NOT Open Access
Author(s): 
Marta Figueiras, Lis Coelho, Alexandra Paulo, et al.
Reference: 
Bioorganic & Medicinal Chemistry Volume 23, Issue 7, 1 April 2015, Pages 1530–1539

We recently reported that potent N10,O11-bis-alkylamine indolo[3,2-b]quinoline antimalarials act as hemozoin (Hz) growth inhibitors.

Medical Treatment: 

“…still waiting for chloroquine”: the challenge of communicating changes in first-line treatment policy for uncomplicated malaria in a remote Kenyan district

July 22, 2014 - 05:32 -- Open Access
Tags: 
Author(s): 
Okungu V, Gilson L
Reference: 
Malaria Journal 2014, 13 :258 (8 July 2014)

Effective health policy communication is important for the uptake of new drug interventions and adherence to treatment regimens.

Country: 
Medical Treatment: 

NOT Open Access | Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain

July 1, 2014 - 12:39 -- NOT Open Access
Author(s): 
Manish Sinha, Vasanth R. Dola, Pooja Agarwal, Kumkum Srivastava, Wahajul Haq, Sunil K. Puri, Seturam B. Katti
Reference: 
Bioorganic & Medicinal Chemistry Volume 22, Issue 14, 15 July 2014, Pages 3573–3586

Emergence and spread of multidrug resistant strains of Plasmodium falciparum has severely limited the antimalarial chemotherapeutic options.

Medical Treatment: 

NOT Open Access | In vivo antimalarial activity of Trichilia megalantha harms extracts and fractions in animal models

August 12, 2013 - 12:39 -- NOT Open Access
Author(s): 
Dorcas A. Fadare, Oyindamola O. Abiodun & Edith O. Ajaiyeoba
Reference: 
Parasitology Research, August 2013, Volume 112, Issue 8, pp 2991-2995
MalariaWorld

The crude methanol extracts of leaf, stem bark, root bark and stem bark fractions of Trichilia megalantha (Meliaceae) were screened for in vivo antimalarial activities in mice against a chloroquine resistant Plasmodium berghei berghei ANKA clone using the 4-day suppressive test procedure.

Medical Treatment: 

Not Open Access | Blood Stage of Plasmodium vivax in Central China Is Still Susceptible to Chloroquine Plus Primaquine Combination Therapy

July 29, 2013 - 18:32 -- NOT Open Access
Author(s): 
Guoding Zhu, Feng Lu, Jun Cao, Huayun Zhou, Yaobao Liu, Eun-Taek Han ,Qi Gao
Reference: 
Am J Trop Med Hyg 2013 89:184-187
MalariaWorld

To measure the effectiveness and safety of CQ-PQ among vivax malaria patients, a total of 39 subjects with monoinfection vivax malaria was enrolled in a study from 2008 to 2009. There were no recrudescence or danger signs observed within the 28-day follow-up period, showing that blood stage of P. vivax isolates from central China is still susceptible to CQ plus PQ combination therapy.

Country: 
Medical Treatment: 

NOT Open Access | Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system

July 17, 2013 - 12:53 -- NOT Open Access
Author(s): 
Graham Freimanis, Mary Sedegah, Shirley Owusu-Ofori, Sanjai Kumar and Jean-Pierre Allain
Reference: 
Transfusion, Volume 53, Issue 7, pages 1429–1441, July 2013
MalariaWorld

None of the currently available screening assays appear suitable to minimize transfusion malaria without compromising the blood supply in endemic areas.

Medical Treatment: 

Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity

May 8, 2013 - 11:41 -- Open Access
Author(s): 
Else M. Bijker, Guido J. H. Bastiaens, Robert W. Sauerwein, et al.
Reference: 
PNAS May 7, 2013 vol. 110 no. 19 7862-7867
MalariaWorld

Volunteers immunized under chloroquine chemoprophylaxis with Plasmodium falciparum sporozoites (CPS) develop complete, long-lasting protection against homologous sporozoite challenge.

Medical Treatment: 

NOT Open Access | Biological assay of a novel quinoxalinone with antimalarial efficacy on Plasmodium yoelii yoelii

March 19, 2013 - 11:24 -- NOT Open Access
Author(s): 
Norma Rivera, Yovani Marrero Ponce, Vicente J. Arán, Cecilia Martínez & Filiberto Malagón
Reference: 
Parasitology Research, April 2013, Volume 112, Issue 4, pp 1523-1527
MalariaWorld

Compound 1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4-dihydroquinoxalin-2(1H)-one (VAM2-6) was evaluated against a blood-induced infection with chloroquine-sensitive Plasmodium yoelii yoelii lethal strain in CD1 mice in a 4-day test scheme.

Medical Treatment: 

Pages

Subscribe to RSS - chloroquine